Earnings summaries and quarterly performance for Personalis.
Executive leadership at Personalis.
Christopher Hall
Detailed
Chief Executive Officer and President
CEO
AT
Aaron Tachibana
Detailed
Chief Financial Officer and Chief Operating Officer
RC
Richard Chen
Detailed
Executive Vice President, Research and Development, and Chief Medical Officer
SM
Stephen Moore
Detailed
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Board of directors at Personalis.
Research analysts who have asked questions during Personalis earnings calls.
Thomas Flaten
Lake Street Capital Markets
6 questions for PSNL
Also covers: ACHV, AQST, ASRT +13 more
Mark Massaro
BTIG, LLC
3 questions for PSNL
Also covers: ADPT, AKYA, BLLN +20 more
Subbu Nambi
Guggenheim Securities
3 questions for PSNL
Also covers: ADPT, BOLD, BRKR +21 more
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
3 questions for PSNL
Also covers: ABSI, BSEM, CGEN +24 more
YO
Yuko Oku
Morgan Stanley
3 questions for PSNL
Also covers: ADPT, GH, GRAL +7 more
Bill Bonello
Craig-Hallum Capital Group LLC
2 questions for PSNL
Also covers: ADPT, BDSX, CDNA +8 more
Daniel Brennan
TD Cowen
2 questions for PSNL
Also covers: A, ADPT, AVTR +25 more
JK
Jason Kritzer
Morgan Stanley
2 questions for PSNL
J
Joseph
ROTH Capital
2 questions for PSNL
Also covers: AOUT, NEO, THRM
Joseph Conway
Needham & Company, LLC
2 questions for PSNL
Also covers: AORT, ATRC, ENOV +6 more
TS
Tom Stevens
Cowen and Company
2 questions for PSNL
Also covers: PACB
Vidyun Bais
BTIG
2 questions for PSNL
Also covers: AKYA, BNGO, CERS +6 more
JF
Joseph Flanagan
TD Cowen
1 question for PSNL
Madison Pasterchick
Morgan Stanley
1 question for PSNL
Also covers: MYGN
Mike Matson
Needham & Company, LLC
1 question for PSNL
Also covers: AORT, ATRC, CNMD +19 more
William Bonello
Craig-Hallum Capital Group
1 question for PSNL
Also covers: BDSX, CDNA, CERS +6 more
WR
William Ruby
TD Cowen
1 question for PSNL
Also covers: BDSX, PACB, SERA +1 more
Recent press releases and 8-K filings for PSNL.
Personalis Announces Q4 and Full Year 2025 Results and 2026 Guidance
PSNL
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Personalis reported Q4 2025 revenue of $17.3 million and full-year 2025 revenue of $69.6 million, with clinical tests growing 329% year-over-year in Q4 2025 to 6,183 tests and 394% for the full year to over 16,000 tests.
- The company secured Medicare coverage for breast cancer in Q4 2025 and lung cancer in early 2026, which is expected to convert volume into higher-margin revenue and supports the strategy to accelerate market share gains.
- For full-year 2026, Personalis projects total revenue of $78 million-$80 million, with clinical revenue of $10 million-$11 million and biopharma MRD revenue of $20 million-$21 million.
- Clinical test volume is guided to 43,000-45,000 tests in 2026, an approximate 170% increase year-over-year, while the company expects a net loss of approximately $105 million and cash usage of around $100 million for the year, with $240 million in cash and short-term investments at the end of Q4 2025.
1 day ago
Personalis Announces Q4 and Full Year 2025 Results and 2026 Guidance
PSNL
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Personalis reported Q4 2025 revenue of $17.3 million and full-year 2025 revenue of $69.6 million, navigating a planned decline in revenue from Natera and the conclusion of the Moderna melanoma trial.
- Clinical test volumes saw substantial growth, with 6,183 tests delivered in Q4 2025, marking a 329% increase year-over-year, and over 16,000 clinical tests for the full year 2025, representing 394% growth over 2024.
- For 2026, the company projects total revenue between $78 million and $80 million, with clinical revenue expected to be $10 million-$11 million and biopharma MRD revenue in the range of $20 million-$21 million.
- Personalis anticipates 43,000-45,000 clinical tests in 2026, an approximate 170% year-over-year growth, and expects a net loss of approximately $105 million with cash usage of about $100 million.
- The company ended Q4 2025 with $240 million in cash and short-term investments and is intentionally investing to gain market share in the MRD testing market, accepting temporary gross margin compression ahead of full reimbursement.
1 day ago
Personalis Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
PSNL
Earnings
Guidance Update
New Projects/Investments
- Personalis (PSNL) reported Q4 2025 total revenue of $17.3 million and full-year 2025 revenue of $69.6 million, with a net loss of $23.8 million for Q4 2025 and $81.3 million for the full year.
- The company experienced significant clinical test volume growth, delivering 6,183 clinical tests in Q4 2025 (a 329% increase year-over-year) and over 16,000 clinical tests for the full year 2025 (a 394% increase over 2024).
- Personalis secured Medicare coverage for breast cancer in Q4 2025 and lung cancer in early 2026, validating its NeXT Personal test for ongoing cancer surveillance.
- For 2026, the company forecasts total revenue in the range of $78 million-$80 million, with clinical revenue of $10 million-$11 million specifically from breast and lung cancer surveillance tests, and anticipates a net loss of approximately $105 million.
- The company concluded Q4 2025 with $240 million in cash and short-term investments and expects cash usage of approximately $100 million in 2026 to accelerate volume and gain market share.
1 day ago
Personalis, Inc. Reports Q4 and Full Year 2025 Results and Provides 2026 Guidance
PSNL
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Personalis, Inc. reported total revenue of $17.3 million for the fourth quarter of 2025 and $69.6 million for the full year 2025, compared to $16.8 million and $84.6 million for the respective periods in 2024. The company recorded a net loss of $23.8 million in Q4 2025 and $81.3 million for the full year 2025.
- Clinical test volume significantly increased, surging 41% in Q4 2025 over Q3 2025 to 6,183 tests, and full year 2025 volume grew nearly 400% to 16,233 tests. The company also secured Medicare coverage for breast and lung cancer surveillance.
- Personalis ended 2025 with a strong cash position of approximately $240 million.
- For the full year 2026, Personalis expects total company revenue in the range of $78.0 million to $80.0 million. Clinical revenue is projected to grow approximately five-fold to $10.0 million to $11.0 million, with clinical volume expected to be in the range of 43,000 to 45,000 tests. The company anticipates a net loss of approximately $105.0 million and cash usage of approximately $100.0 million for 2026.
1 day ago
Personalis Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
PSNL
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Personalis reported full year 2025 total revenue of $69.6 million and a net loss of $81.270 million, while clinical test volume increased nearly 400% to 16,233 tests.
- The company ended 2025 with a strong cash position of approximately $240 million and secured Medicare coverage for breast and lung cancer surveillance, which are expected to be key catalysts for clinical revenue growth.
- For full year 2026, Personalis projects total revenue between $78.0 and $80.0 million, with clinical revenue expected to grow approximately five-fold to $10.0 to $11.0 million, and anticipates a net loss of approximately $105.0 million.
1 day ago
Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance
PSNL
Product Launch
Revenue Acceleration/Inflection
- Personalis (PSNL) announced on February 10, 2026, that its NeXT Personal molecular residual disease (MRD) test has received Medicare coverage for the surveillance of patients with Stage I to III non-small cell lung cancer (NSCLC).
- This coverage is supported by clinical evidence from the TRACERx consortium, which demonstrated NeXT Personal's high accuracy in identifying residual disease in lung cancer.
- According to CEO Chris Hall, this development broadens patient access to the test for a common cancer and serves as a catalyst for the company's continued growth.
- The NeXT Personal test utilizes whole-genome sequencing and advanced noise-suppression technology to detect trace amounts of circulating tumor DNA (ctDNA) by tracking up to ~1800 mutations.
Feb 10, 2026, 11:00 AM
Personalis, Inc. Reports Preliminary Fourth Quarter and Full Year 2025 Results
PSNL
Earnings
Revenue Acceleration/Inflection
- Personalis, Inc. reported preliminary fourth quarter 2025 revenue in the range of $17 million to $18 million and preliminary full year 2025 revenue in the range of $69 million to $70 million.
- Clinical test volume surged to 6,183 tests in Q4 2025, marking a 41% sequential increase over Q3 2025, and reached 16,233 tests for the full year 2025, a nearly 400% increase compared to 2024.
- The company secured pivotal Medicare coverage for breast cancer surveillance, validating its ultrasensitive MRD technology.
- Personalis, Inc. maintained a strong liquidity position, ending 2025 with approximately $240 million in cash, cash equivalents, and short-term investments.
Jan 8, 2026, 1:05 PM
Personalis Reports Preliminary Fourth Quarter and Full Year 2025 Results
PSNL
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Personalis reported preliminary fourth quarter 2025 revenue of $17 to $18 million and preliminary full year 2025 revenue of $69 to $70 million.
- Clinical test volume surged 41% in Q4 2025 over Q3 2025 to 6,183 tests, with full year volume reaching 16,233 tests, a nearly 400% increase over 2024.
- The company ended 2025 with a strong cash position of approximately $240 million.
- Personalis secured pivotal Medicare coverage for breast cancer surveillance, validating its ultrasensitive MRD technology.
Jan 8, 2026, 1:00 PM
Personalis Announces Publication on NeXT Personal Ultrasensitive Detection in Lung Cancer
PSNL
Product Launch
New Projects/Investments
- Personalis, Inc. announced the publication of a study in the journal Cell demonstrating the clinical importance of its NeXT Personal ultrasensitive, tumor-informed molecular residual disease (MRD) testing in stage I to III non-small cell lung cancer (NSCLC).
- The landmark TRACERx study, which analyzed 431 NSCLC patients for a median of over 5 years, showed NeXT Personal's high sensitivity for detecting circulating tumor DNA (ctDNA) from diagnosis through surveillance.
- The NeXT Personal test demonstrated exceptional sensitivity and specificity, detecting cancer a median of ~5 to ~9 months and up to ~57 months ahead of standard of care imaging post-surgery and during surveillance.
- Ultrasensitive ctDNA detection by NeXT Personal was associated with a higher risk of relapse and worse overall survival, and identified an intermediate risk patient subgroup.
- Patients who did not clear their ctDNA during adjuvant chemotherapy were over 5 times more likely to relapse than those who cleared it.
Dec 11, 2025, 2:00 PM
Personalis' NeXT Personal Test Gains Medicare Coverage
PSNL
Product Launch
Revenue Acceleration/Inflection
- On November 7, 2025, Personalis, Inc.'s ultrasensitive NeXT Personal® test received Medicare coverage.
- This coverage, effective retroactively as of October 7, 2025, is for post-treatment surveillance of cancer recurrence in patients with stage II and III breast cancer.
- The Centers for Medicare & Medicaid Services Molecular Diagnostics Program determined reimbursement rates of $3,878 for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and $1,158 for the NeXT Personal Single Plasma Test.
Nov 10, 2025, 2:11 PM
Quarterly earnings call transcripts for Personalis.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more